UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Sells 38,887 Shares of Hologic, Inc. $HOLX

Key Points

• UBS Asset Management reduced its stake in Hologic, Inc. by 1.7%, holding approximately 2.25 million shares valued at $138.7 million after selling 38,887 shares in the first quarter.
• Notable institutional investors, including Victory Capital Management and Invesco Ltd., have increased their stakes in Hologic, highlighting a trend of growing investor interest.
• Analysts maintain a Moderate Buy consensus rating for Hologic, with target price projections ranging from $70.00 to $80.00 following recent upgrades from firms like Argus and Citigroup.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC cut its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 1.7% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,245,344 shares of the medical equipment provider's stock after selling 38,887 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 1.01% of Hologic worth $138,695,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Zions Bancorporation National Association UT acquired a new stake in shares of Hologic in the first quarter valued at $34,000. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Hologic in the first quarter valued at $42,000. Raiffeisen Bank International AG acquired a new stake in shares of Hologic in the fourth quarter valued at $49,000. Allworth Financial LP boosted its holdings in Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after acquiring an additional 216 shares during the last quarter. Finally, Larson Financial Group LLC boosted its holdings in Hologic by 6,016.7% in the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock valued at $45,000 after acquiring an additional 722 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Trading Down 1.0%

HOLX traded down $0.65 during midday trading on Monday, reaching $63.80. 1,276,134 shares of the company were exchanged, compared to its average volume of 1,330,759. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.39. The stock has a market capitalization of $14.19 billion, a P/E ratio of 26.47, a PEG ratio of 2.34 and a beta of 0.57. The stock's 50-day simple moving average is $66.42 and its 200 day simple moving average is $62.64.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter last year, the business earned $1.06 earnings per share. The company's revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HOLX has been the topic of several recent research reports. Evercore ISI raised their price target on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a report on Tuesday, July 8th. Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and raised their price target for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. Argus upgraded Hologic from a "hold" rating to a "buy" rating and set a $80.00 price target on the stock in a report on Monday, August 18th. Mizuho set a $75.00 price target on Hologic in a report on Thursday, July 31st. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $78.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.